
    
      This study is an open-label, non-randomized dose escalation and expansion study of the LSD
      inhibitor SP-2577 in combination with the anti PD- 1 antibody pembrolizumab in patients with
      advanced, recurrent small cell ovarian cancer of the hypercalcemic type (SCCOHT) as well as
      select additional ovarian and endometrial cancers with mutations in the genes within the
      SWI/SNF pathway (Ovarian Clear Cell Cancers (OCCC), Endometrioid Ovarian Cancers (EOC) and
      Endometrioid Endometrial Cancers (EEC).
    
  